Trial · NCT04590586
Outcomes33
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 33
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 | Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29 | The lanadelumab sub-protocol primary analysis set includes all participants who were randomized to lanadelumab as well as all participants who were randomized to any placebo arm included in the control arm for lanadelumab with a baseline clinical severity status of Grade 3 to Grade 5 on the clinical severity status 8-point ordinal scale. | days | MEDIAN |
| PRIMARY | Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 | Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29 | The apremilast full analysis set (FAS) includes all participants who were randomized to the apremilast arm as well as all participants who were randomized to any placebo arm included in the control arm for apremilast. | days | MEDIAN |
| PRIMARY | Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 | Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29 | The zilucoplan full analysis set includes all participants who were randomized to the zilucoplan arm as well as all participants who were randomized to any placebo arm included in the control arm for zilucoplan. | days | MEDIAN |
| SECONDARY | Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29 | Day 29 | Lanadelumab sub-protocol primary analysis set | percentage of participants | NUMBER |
| SECONDARY | Lanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29 | Baseline (Day 1) and Day 29 | Lanadelumab sub-protocol primary analysis set | percentage of participants | NUMBER |
| SECONDARY | Lanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 29 | Day 1 to Day 29 | Lanadelumab sub-protocol primary analysis set | percentage of participants | NUMBER |
| SECONDARY | Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29 | Day 8, Day 15, and Day 29 | Lanadelumab sub-protocol primary analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Lanadelumab Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-point Ordinal Scale From Baseline to Day 29 | Day 2 to Day 29 | Lanadelumab sub-protocol primary analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Lanadelumab Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29 | Day 1 to Day 29 | Lanadelumab sub-protocol primary analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Lanadelumab Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29 | Day 1 to Day 29 | Lanadelumab sub-protocol primary analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29 | Day 8, Day 15, and Day 29 | Lanadelumab sub-protocol primary analysis set | percentage of participants | NUMBER |
| SECONDARY | Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery | Day 60 | Lanadelumab sub-protocol primary analysis set | percentage of participants | NUMBER |
| SECONDARY | Lanadelumab Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | From first dose of study drug to end of study (Day 60) | Lanadelumab safety analysis set included all participants in the lanadelumab FAS who received at least one dose of study drug. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Apremilast Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29 | Day 29 | Apremilast sub-protocol full analysis set | percentage of participants | NUMBER |
| SECONDARY | Apremilast Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29 | Baseline (Day 1) and Day 29 | Apremilast sub-protocol full analysis set | percentage of participants | NUMBER |
| SECONDARY | Apremilast Sub-protocol: Percentage of Participants Who Died Before or on Day 29 | Day 1 to Day 29 | Apremilast sub-protocol full analysis set | percentage of participants | NUMBER |
| SECONDARY | Apremilast Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29 | Day 8, Day 15, and Day 29 | Apremilast sub-protocol full analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Apremilast Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29 | Day 2 to Day 29 | Apremilast sub-protocol full analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Apremilast Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29 | Day 1 to Day 29 | Apremilast sub-protocol full analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Apremilast Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29 | Day 1 to Day 29 | Apremilast sub-protocol full analysis set | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04590586/outcomes